ESR1 and breast cancer: With respect to the MAPK/ERK pathway, Raffo et al.40 reported that the MAPK/ERK pathway was activated within 10 min of administering 10 nM E2 in 2 breast cancer cell lines, namely MCF-7 and LM05-E cells (ER+, PR+).